Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1863
http://purl.obolibrary.org/obo/NCIT_C1863
|
|---|---|
| Preferred Name | Entinostat |
| Definitions |
A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic benzamide derivative with potential antineoplastic activity. Entinostat binds to and inhibits histone deacetylase, an enzyme that regulates chromatin structure and gene transcription. This agent appears to exert dose-dependent effects in human leukemia cells including cyclin-dependent kinase inhibitor 1A (p21/CIP1/WAF1)-dependent growth arrest and differentiation at low drug concentrations; a marked induction of reactive oxygen species (ROS); mitochondrial damage; caspase activation; and, at higher concentrations, apoptosis. In normal cells, cyclin-dependent kinase inhibitor 1A expression has been associated with cell-cycle exit and differentiation. |
|---|---|
| prefLabel | Entinostat
|
| label | Entinostat
|
| PDQ_Closed_Trial_Search_ID | 38294
|
| code | C1863
|
| Has_Target | |
| prefixIRI | NCIT:C1863
|
| in_subset |
See more
See less
|
| Display_Name | Entinostat
|
| Preferred_Name | Entinostat
|
| FDA_UNII_Code | 1ZNY4FKK9H
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C21H20N4O3
|
| Maps_To | Entinostat
|
| CAS_Registry | 209783-80-2
|
| NSC Number | 706995
|
| NCI_Drug_Dictionary_ID | 38294
|
| Legacy Concept Name | MS-27-275
|
| type | |
| ALT_DEFINITION | A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38294
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C4048552
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |